Antagonists of bone morphogenetic proteins in kidney disease

Current Opinion in Investigational Drugs

Volumn 11, Issue 3, 2010, Pages 315-322

  Yanagita, M ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

BMP 7; Bone morphogenetic protein; Chordin like 1; Crim1; Follistatin; Gremlin; KCP; Kidney disease; USAG 1

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN RECEPTOR; BONE MORPHOGENETIC PROTEIN RECEPTOR 1A; BONE MORPHOGENETIC PROTEIN RECEPTOR 1B; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; FOLLISTATIN; GLYCOPROTEIN; MEMBRANE PROTEIN; OSTEOGENIC PROTEIN 1; PROTEIN CHORDIN LIKE 1; PROTEIN CRIM1; PROTEIN GREMLIN; PROTEIN KIELIN; RECOMBINANT OSTEOGENIC PROTEIN 1; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG PROTEIN BINDING; GENE; GLOMERULUS; KIDNEY CARCINOMA; KIDNEY DEVELOPMENT; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY PROXIMAL TUBULE; MORPHOGENESIS; NONHUMAN; PROTEIN FUNCTION; RENAL PROTECTION; REVIEW; SIGNAL TRANSDUCTION; TISSUE REGENERATION; UTERINE SENSITIZATION ASSOCIATED GENE 1;

ANIMALS; BONE MORPHOGENETIC PROTEIN 7; BONE MORPHOGENETIC PROTEINS; HUMANS; KIDNEY DISEASES;

EID: 77649098228     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, Kalluri R: BMP-7 counteracts TGF-ß1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med (2003) 9(7):964-968.
2. Klahr S: The bone morphogenetic proteins (BMPs). Their role in renal fibrosis and renal function. J Nephrol (2003) 16(2):179-185.
3. Hruska KA, Saab G, Chaudhary LR, Quinn CO, Lund RJ, Surendran K: Kidney-bone, bone-kidney, and cell-cell communications in renal osteodystrophy. Semin Nephrol (2004) 24(1):25-38.
4. Zeisberg M, Muller GA, Kalluri R: Are there endogenous molecules that protect kidneys from injury? The case for bone morphogenic protein-7 (BMP-7). Nephrol Dial Transplant (2004) 19(4):759-761.
5. Yanagita M: Modulator of bone morphogenetic protein activity in the progression of kidney diseases. Kidney Int (2006) 70(6):989-993.
6. Yanagita M: BMP antagonists: Their roles in development and involvement in pathophysiology. Cytokine Growth Factor Rev (2005) 16(3):309-317.
7. Danesh SM, Villasenor A, Chong D, Soukup C, Cleaver O: BMP and BMP receptor expression during murine organogenesis. Gene Expression Patterns (2009) 9(5):255-265.
8. Balemans W, Van Hul W: Extracellular regulation of BMP signaling in vertebrates: A cocktail of modulators. Dev Biol (2002) 250(2):231-250.
9. Luo G, Hofmann C, Bronckers AL, Sohocki M, Bradley A, Karsenty G: BMP-7 is an inducer of nephrogenesis, and is also required for eye development and skeletal patterning. Genes Dev (1995) 9(22):2808-2820.
10. Dudley AT, Lyons KM, Robertson EJ: A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye. Genes Dev (1995) 9(22):2795-2807.
11. Gould SE, Day M, Jones SS, Dorai H: BMP-7 regulates chemokine, cytokine, and hemodynamic gene expression in proximal tubule cells. Kidney Int (2002) 61(1):51-60.
12. Vukicevic S, Basic V, Rogic D, Basic N, Shih MS, Shepard A, Jin D, Dattatreyamurty B, Jones W, Dorai H, Ryan S et al: Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat. J Clin Invest (1998) 102(1):202-214.
13. Simon M, Maresh JG, Harris SE, Hernandez JD, Arar M, Olson MS, Abboud HE: Expression of bone morphogenetic protein-7 mRNA in normal and ischemic adult rat kidney. Am J Physiol (1999) 276(3 Pt 2):F382-F389.
14. Morrissey J, Hruska K, Guo G, Wang S, Chen Q, Klahr S: Bone morphogenetic protein-7 improves renal fibrosis and accelerates the return of renal function. J Am Soc Nephrol (2002) 13(Suppl 1):S14-S21.
15. Wang SN, Lapage J, Hirschberg R: Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy. J Am Soc Nephrol (2001) 12(11):2392-2399.
16. Biyikli NK, Tugtepe H, Cakalagaoglu F, Ilki A, Alpay H: Downregulation of the expression of bone morphogenetic protein 7 in experimental pyelonephritis. Pediatr Nephrol (2005) 20(9):1230-1236.
17. Tuǧlular S, Gogas Yavuz D, Cakalaǧaoǧlu F, Citak L, Arikan H, Koçak H, Ozener C, Akoǧlu E: Cyclosporine-A induced nephrotoxicity is associated with decreased renal bone morphogenetic protein-7 expression in rats. Transplant Proc (2004) 36(1):131-133.
18. Hruska KA: Treatment of chronic tubulointerstitial disease: A new concept. Kidney Int (2002) 61(5):1911-1922.
19. Hruska KA, Guo G, Wozniak M, Martin D, Miller S, Liapis H, Loveday K, Klahr S, Sampath TK, Morrissey J: Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. Am J Physiol Renal Physiol (2000) 279(1):F130-F143.
20. Wang S, Chen Q, Simon TC, Strebeck F, Chaudhary L, Morrissey J, Liapis H, Klahr S, Hruska KA: Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int (2003) 63(6):2037-2049.
21. Zeisberg M, Bottiglio C, Kumar N, Maeshima Y, Strutz F, Müller GA, Kalluri R: Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am J Physiol Renal Physiol (2003) 285(6):F1060-F1067.
22. Dube PH, Almanzar MM, Frazier KS, Jones WK, Charette MF, Paredes A: Osteogenic protein-1: Gene expression and treatment in rat remnant kidney model. Toxicol Pathol (2004) 32(4):384-392.
23. Eddy AA: Ramping up endogenous defences against chronic kidney disease. Nephrol Dial Transplant (2006) 21(5):1174-1177.
24. Wang S, de Caestecker M, Kopp J, Mitu G, Lapage J, Hirschberg R: Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J Am Soc Nephrol (2006) 17(9):2504-2512.
25. Sugimoto H, Grahovac G, Zeisberg M, Kalluri R: Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes (2007) 56(7):1825-1833.
26. Ikeda Y, Jung YO, Kim H, Oda T, López-Guisa J, Maruvada R, Diamond DL, Martin KJ, Wing D, Cai X, Eddy AA: Exogenous bone morphogenetic protein-7 fails to attenuate renal fibrosis in rats with overload proteinuria. Nephron (2004) 97(4):e123-e135.
27. De Petris L, Hruska KA, Chiechio S, Liapis H: Bone morphogenetic protein-7 delays podocyte injury due to high glucose. Nephrol Dial Transplant (2007) 22(12):3442-3450.
28. Mitu GM, Wang S, Hirschberg R: BMP7 is a podocyte survival factor and rescues podocytes from diabetic injury. Am J Physiol Renal Physiol (2007) 293(5):F1641-F1648.
29. Zeisberg M, Shah AA, Kalluri R: Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. J Biol Chem (2005) 280(9):8094-8100.
30. Zhang XL, Selbi W, de la Motte C, Hascall V, Phillips AO: Bone morphogenic protein-7 inhibits monocyte-stimulated TGF-?1 generation in renal proximal tubular epithelial cells. J Am Soc Nephrol (2005) 16(1):79-89.
31. Selbi W, de la Motte C, Hascall V, Phillips A: BMP-7 modulates hyaluronan-mediated proximal tubular cell-monocyte interaction. J Am Soc Nephrol (2004) 15(5):1199-1211.
32. Wang S, Hirschberg R: Bone morphogenetic protein-7 signals opposing transforming growth factor β in mesangial cells. J Biol Chem (2004) 279(22):23200-23206.
33. Chan WL, Leung JC, Chan LY, Tam KY, Tang SC, Lai KN: BMP-7 protects mesangial cells from injury by polymeric IgA. Kidney Int (2008) 74(8):1026-1039.
34. Yeh CH, Chang CK, Cheng MF, Lin HJ, Cheng JT: The antioxidative effect of bone morphogenetic protein-7 against high glucose-induced oxidative stress in mesangial cells. Biochem Biophys Res Commun (2009) 382(2):292-297.
35. Bosukonda D, Shih MS, Sampath KT, Vukicevic S: Characterization of receptors for osteogenic protein-1/bone morphogenetic protein-7 (OP-1/BMP-7) in rat kidneys. Kidney Int (2000) 58(5):1902-1911.
36. Avsian-Kretchmer O, Hsueh AJ: Comparative genomic analysis of the eight-membered ring cystine knot-containing bone morphogenetic protein antagonists. Mol Endocrinol (2004) 18(1):1-12.
37. Yanagita M: Balance between bone morphogenetic proteins and their antagonists in kidney injury. Ther Apher Dial (2007) 11(Suppl 1):S38-S43.
38. Yanagita M: BMP modulators regulate the function of BMP during body patterning and disease progression. BioFactors (2009) 35(2):113-119.
39. Simmons DG, Kennedy TG: Uterine sensitization-associated gene-1: A novel gene induced within the rat endometrium at the time of uterine receptivity/sensitization for the decidual cell reaction. Biol Reprod (2002) 67(5):1638-1645.
40. Yanagita M, Oka M, Watabe T, Iguchi H, Niida A, Takahashi S, Akiyama T, Miyazono K, Yanagisawa M, Sakurai T: USAG-1: A bone morphogenetic protein antagonist abundantly expressed in the kidney. Biochem Biophys Res Commun (2004) 316(2):490-500.
41. Laurikkala J, Kassai Y, Pakkasjarvi L, Thesleff I, Itoh N: Identification of a secreted BMP antagonist, ectodin, integrating BMP, FGF, and SHH signals from the tooth enamel knot. Dev Biol (2003) 264(1):91-105.
42. Yanagita M, Okuda T, Endo S, Tanaka M, Takahashi K, Sugiyama F, Kunita S, Takahashi S, Fukatsu A, Yanagisawa M, Kita T et al: Uterine sensitization-associated gene-1 (USAG-1), a novel BMP antagonist expressed in the kidney, accelerates tubular injury. J Clin Invest (2006) 116(1):70-79.
43. Tanaka M, Endo S, Okuda T, Economides AN, Valenzuela DM, Murphy AJ, Robertson E, Sakurai T, Fukatsu A, Yancopoulos GD, Kita T et al: Expression of BMP-7 and USAG-1 (a BMP antagonist) in kidney development and injury. Kidney Int (2008) 73(2):181-191.
44. Blish KR, Wang W, Willingham MC, Du W, Birse CE, Krishnan SR, Brown JC, Hawkins GA, Garvin AJ, D'Agostino RB Jr, Torti FM et al: A human bone morphogenetic protein antagonist is down-regulated in renal cancer. Mol Biol Cell (2008) 19(2): 457-464.
45. Hsu DR, Economides AN, Wang X, Eimon PM, Harland RM: The Xenopus dorsalizing factor gremlin identifies a novel family of secreted proteins that antagonize BMP activities. Mol Cell (1998) 1(5):673-683.
46. Carvajal G, Droguett A, Burgos ME, Aros C, Ardiles L, Flores C, Carpio D, Ruiz-Ortega M, Egido J, Mezzano S: Gremlin: A novel mediator of epithelial mesenchymal transition and fibrosis in chronic allograft nephropathy. Transplant Proc (2008) 40(3):734-739.
47. Dolan V, Murphy M, Sadlier D, Lappin D, Doran P, Godson C, Martin F, O'Meara Y, Schmid H, Henger A, Kretzler M et al: Expression of gremlin, a bone morphogenetic protein antagonist, in human diabetic nephropathy. Am J Kidney Dis (2005) 45(6):1034-1039.
48. Mezzano S, Droguett A, Burgos ME, Aros C, Ardiles L, Flores C, Carpio D, Carvajal G, Ruiz-Ortega M, Egido J: Expression of gremlin, a bone morphogenetic protein antagonist, in glomerular crescents of pauci-immune glomerulonephritis. Nephrol Dial Transplant (2007) 22(7):1882-1890.
49. Jara A, Chacón C, Burgos ME, Droguett A, Valdivieso A, Ortiz M, Troncoso P, Mezzano S: Expression of gremlin, a bone morphogenetic protein antagonist, is associated with vascular calcification in uraemia. Nephrol Dial Transplant 2009:24(4):1121-1129.
50. McMahon R, Murphy M, Clarkson M, Taal M, Mackenzie HS, Godson C, Martin F, Brady HR: IHG-2, a mesangial cell gene induced by high glucose, is human gremlin. Regulation by extracellular glucose concentration, cyclic mechanical strain, and transforming growth factor-α1. J Biol Chem (2000) 275(14):9901-9904.
51. Michos O, Panman L, Vintersten K, Beier K, Zeller R, Zuniga A: Gremlin-mediated BMP antagonism induces the epithelialmesenchymal feedback signaling controlling metanephric kidney and limb organogenesis. Development (2004) 131(14):3401-3410.
52. Roxburgh SA, Kattla JJ, Curran SP, O'Meara YM, Pollock CA, Goldschmeding R, Godson C, Martin F, Brazil DP: Allelic depletion of grem1 attenuates diabetic kidney disease. Diabetes (2009) 58(7)1641-1650.
53. Piccolo S, Sasai Y, Lu B, De Robertis EM: Dorsoventral patterning in Xenopus: Inhibition of ventral signals by direct binding of chordin to BMP-4. Cell (1996) 86(4):589-598.
54. Sasai Y, Lu B, Piccolo S, De Robertis EM: Endoderm induction by the organizer-secreted factors chordin and noggin in Xenopus animal caps. Embo J (1996)15(17):4547-4555.
55. Wardle FC, Welch JV, Dale L: Bone morphogenetic protein 1 regulates dorsal-ventral patterning in early Xenopus embryos by degrading chordin, a BMP4 antagonist. Mech Dev (1999) 86(1-2):75-85.
56. Gazzerro E, Canalis E: Bone morphogenetic proteins and their antagonists. Rev Endocr Metab Disord (2006) 7(1-2):51-65.
57. Turk T, Leeuwis JW, Gray J, Torti SV, Lyons KM, Nguyen TQ, Goldschmeding R: BMP signaling and podocyte markers are decreased in human diabetic nephropathy in association with CTGF overexpression. J Histochem Cytochem (2009) 57(7)623-631.
58. Larman BW, Karolak MJ, Adams DC, Oxburgh L: Chordin-like 1 and twisted gastrulation 1 regulate BMP signaling following kidney injury. J Am Soc Nephrol (2009) 20(5):1020-1031.
59. Wilkinson L, Kolle G, Wen D, Piper M, Scott J, Little M: CRIM1 regulates the rate of processing and delivery of bone morphogenetic proteins to the cell surface. J Biol Chem (2003) 278(36):34181-34188.
60. Pennisi DJ, Wilkinson L, Kolle G, Sohaskey ML, Gillinder K, Piper MJ, McAvoy JW, Lovicu FJ, Little MH: Crim1KST264/KST264 mice display a disruption of the Crim1 gene resulting in perinatal lethality with defects in multiple organ systems. Dev Dyn (2007) 236(2):502-511.
61. Wilkinson L, Gilbert T, Kinna G, Ruta LA, Pennisi D, Kett M, Little MH: Crim1KST264/KST264 mice implicate Crim1 in the regulation of vascular endothelial growth factor-A activity during glomerular vascular development. J Am Soc Nephrol (2007) 18(6):1697-1708.
62. Brenchley PE: Vascular permeability factors in steroid-sensitive nephrotic syndrome and focal segmental glomerulosclerosis. Nephrol Dial Transplant (2003) 18 (Suppl 6):vi21-vi25.
63. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM et al: Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med (2004) 350(7):672-683.
64. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP et al: VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med (2008) 358(11):1129-1136.
65. Maeshima A, Miya M, Mishima K, Yamashita S, Kojima I, Nojima Y: Activin A: Autocrine regulator of kidney development and repair. Endocr J (2008) 55(1):1-9.
66. Xia Y, Schneyer AL: The biology of activin: Recent advances in structure, regulation and function. J Endocrinol (2009) 202(1):1-12.
67. Sugino H, Sugino K, Hashimoto O, Shoji H, Nakamura T: Follistatin and its role as an activin-binding protein. J Med Invest (1997) 44(1-2):1-14.
68. Nakamura T, Sugino K, Titani K, Sugino H: Follistatin, an activin-binding protein, associates with heparan sulfate chains of proteoglycans on follicular granulosa cells. J Biol Chem (1991) 266(29):19432-19437.
69. Hashimoto O, Nakamura T, Shoji H, Shimasaki S, Hayashi Y, Sugino H: A novel role of follistatin, an activin-binding protein, in the inhibition of activin action in rat pituitary cells. Endocytotic degradation of activin and its acceleration by follistatin associated with cell-surface heparan sulfate. J Biol Chem (1997) 272(21):13835-13842.
70. Sidis Y, Mukherjee A, Keutmann H, Delbaere A, Sadatsuki M, Schneyer A: Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins. Endocrinology (2006) 147(7): 3586-3597.
71. Kimura F, Sidis Y, Bonomi L, Xia Y, Schneyer A: The follistatin-288 isoform alone is sufficient for survival but not for normal fertility in mice. Endocrinology (2009): doi:10.1210/en.2009-1176.
72. Maeshima A, Zhang YQ, Nojima Y, Naruse T, Kojima I: Involvement of the activin-follistatin system in tubular regeneration after renal ischemia in rats. J Am Soc Nephrol (2001) 12(8):1685-1695. (Pubitemid 32674431)
73. Lin J, Patel SR, Cheng X, Cho EA, Levitan I, Ullenbruch M, Phan SH, Park JM, Dressler GR: Kielin/chordin-like protein, a novel enhancer of BMP signaling, attenuates renal fibrotic disease. Nat Med (2005) 11(4):387-393.
74. Lin J, Patel SR, Wang M, Dressler GR: The cysteine-rich domain protein KCP is a suppressor of transforming growth factor β/activin signaling in renal epithelia. Mol Cell Biol (2006) 26(12):4577-4585.